News
Resources
Blog
Sites
Biopharmaceutical Innovation: Antibody drug conjugates
By Andrew Powaleny | February 29, 2016
Imagine new medicines that effectively fight cancer, but may result in fewer side effects thanks to more accurate targeting of tumor cells. Today, PhRMA released a new video that highlights these...
Read More
Medicare Monday: Part D competition then and now
By Allyson Funk | February 29, 2016
Last week, we looked at what was said about Medicare Part D costs and beneficiary premiums when the program was created – and at what has actually happened in the first 10 years of the program. This...
Read More
Advancing the science for patients with rare diseases
By Allyson Funk | February 29, 2016
When you have a loved one with a rare disease, the importance of persevering to find new, innovative treatments takes on new meaning. This year on Rare Disease Day, I am excited to celebrate the...
Read More
Week in review: The latest from PhRMA
By Priscilla VanderVeer | February 26, 2016
Leading efforts to better understand amyloidosis diseases
By Guest Contributor | February 26, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New report celebrates a decade of progress in chronic diseases
By Holly Campbell | February 25, 2016
In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases. With about half of all Americans, or 117 million people, living with...
Read More
Why neglected tropical disease and rare disease researchers need each other
By Guest Contributor | February 25, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Don’t lie down!
By Guest Contributor | February 24, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday: Part D then and now
By Allyson Funk | February 22, 2016
As we reflect on 10 years since the implementation of Medicare Part D, we’re taking a closer look at what was said in the early years after the law was passed and what actually happened. Over the...
Read More
Week in review: The latest from PhRMA
By Priscilla VanderVeer | February 19, 2016
Coverage does not equal access: While the burden of high deductibles has already received significant attention, new data reveals that consumers have no choice but to pay up to thousands of dollars...
Read More
When coverage does not equal access to care
By Karyn Schwartz | February 19, 2016
Building on recent stories about the challenges even those with insurance are facing, new data show some consumers have no choice but to pay up to thousands of dollars out of pocket before their...
Read More
Time for Canada to catch up on intellectual property
By Mark Grayson | February 18, 2016
Last week, the U.S. Chamber of Commerce’s Global Intellectual Property Center (GIPC) released its fourth annual International IP Index. The Index, which measures the intellectual property (IP)...
Read More
Special Edition Medicare Monday: New report looks at Medicare negotiation proposals
By Nicole Longo | February 17, 2016
In case you missed it, today’s special edition of #MedicareMonday highlights a new issue brief from the Kaiser Family Foundation on how Medicare negotiation proposals would change the structure of...
Read More
Medicare Monday: Celebrating President’s Day with a brief Medicare history
By Nicole Longo | February 15, 2016
This President’s Day, we wanted to look back at three key moments in the history of Medicare. Creation of Part A and Part B: On July 30, 1965, President Lyndon B. Johnson signed into law the Social...
Read More
Week in Review: The latest from PhRMA
By Priscilla VanderVeer | February 12, 2016
Today’s “Week in Review” covers the last two weeks of activity here at PhRMA. As you’ll see, we’ve been busy! We’re Fighting Back: Our new From Hope to Cures ad campaign launched on Monday. In it,...
Read More
The biopharmaceutical industry’s commitment to quality
By Camille Jackson | February 11, 2016
America’s innovative biopharmaceutical companies are leaders in innovation and quality—not just in research and development, but also in manufacturing technology. PhRMA’s member companies implement...
Read More
Canada’s innovation opportunity
By Jay Taylor | February 11, 2016
Next month’s visit of Prime Minister Justin Trudeau to Washington is a chance to strengthen a vital trade and investment partnership and to resolve problems left over by Canada’s previous government....
Read More
Celebrating brighter futures and healthier hearts during American Heart Month
By Hannah Mooney Mack | February 10, 2016
This weekend on Valentine’s Day, we take time to celebrate our friends, family and significant others with acts of love and attention. But we also have the opportunity during American Heart Month to...
Read More
PhRMA Statement on President’s FY2017 Budget
By Stephen J. Ubl | February 9, 2016
The biopharmaceutical industry is committed to advancing solutions for a competitive, value-based health care system that makes better use of today’s medicines and fosters the development of...
Read More
340B Spotlight: 340B hospitals account for majority of Part B reimbursements
By Allyson Funk | February 9, 2016
Once again, new research is pointing to the critical need to reform the 340B program. The latest data, from Berkeley Research Group (BRG), uncovered startling differences in Medicare Part B hospital...
Read More
Medicare Monday: What they are saying about negotiation in Medicare Part D
By Nicole Longo | February 8, 2016
Last week, we highlighted how changing the structure of the Medicare Part D program would cause more harm than good by restricting beneficiary access to needed medicines. Here’s a look at what is...
Read More
Patients and researchers say “we’re fighting back” in new “From Hope to Cures” ads
By Ieva M. Augstums | February 8, 2016
Diagnosed with type 1 diabetes at a young age, five-year-old Rhys has not let his diagnosis be his destiny. He enjoys life to the fullest, from playing sports to having treats at a friend’s birthday...
Read More
Canada’s chance to reform its approach to innovation
By Jay Taylor | February 5, 2016
Intellectual property drives and sustains research, development and delivery of valuable new treatments and cures for patients who need them around the world. America’s world-leading research-based...
Read More
World Cancer Day: Reflecting on progress and hope for the future in cancer treatment
By Nicole Longo | February 4, 2016
More than 1.7 million new cancer cases are expected to be diagnosed in the United States this year. Although that number is daunting, World Cancer Day reminds us that tremendous progress in the...
Read More
340B Spotlight: Hospitals report declines in uncompensated care even as more are qualifying for the 340B drug discount program
By Karyn Schwartz | February 3, 2016
We previously noted that it is counterintuitive that more hospitals would become eligible for the 340B discount program as the share of uninsured patients these hospitals serve declines due to the...
Read More
Medicare Monday: Why changing the structure of Part D could hurt beneficiary access
By Nicole Longo | February 1, 2016
This week on Medicare Monday, we’re looking at how proposals to change the structure of Medicare Part D could actually limit – and hurt – beneficiary access. As we’ve covered before, price...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
